PRICING MISSTEP Novo also drew backlash from insurers, doctors and patients for launching Wegovy in the U.S. at more than $1,300 per month, about $350 more than Ozempic.

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, and valuation discounts.

Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, the company said. Under the deal, Novo will ...

Novo Nordisk (NVO -1.00%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times ...

Novo has agreed to pay up to $812 million, including an upfront payment, research costs and milestones, for a global license to small molecules aimed at a GPCR target that isn’t an incretin. GLP ...

A persistent underground fire at the illegal Krupačke stijene landfill in the Krupac area is sending toxic smoke across western parts of the city.

Novo Nordisk launches new late-stage trial for next-gen weight loss drug CagriSema Jun. 10, 2025 12:11 PM ET Novo Nordisk A/S (NVO) Stock, NONOF Stock By: Dulan Lokuwithana, SA News Editor 7 Comments ...

In January, Novo recorded 22% weight loss in people who received weekly amycretin injections for 36 weeks in a phase 1b/2a study. The company didn’t mention whether weight loss appeared to ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both jumped 0 ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...